Joseph Walter Vazzano, the Chief Financial Officer of Abeona Therapeutics Inc (NASDAQ:ABEO), completed a sale of 18,666 shares of the company’s common stock on January 22, 2026, as documented in a recent Securities and Exchange Commission filing. The total proceeds from the transaction were approximately $99,506.
The shares were disposed of at an average price of $5.3309 per share, with individual sale prices varying slightly from $5.33 to $5.38. This transaction was initiated specifically to fulfill tax liabilities arising from the vesting of restricted stock awards granted to Vazzano. Following this sale, he retains direct ownership of 568,560 shares of Abeona Therapeutics, maintaining a substantial personal stake in the company.
In addition to this insider activity, Abeona Therapeutics recently announced its financial results for the third quarter of 2025, reporting earnings per share (EPS) of -$0.10. This performance surpassed the consensus forecast of -$0.27 per share, marking a significant improvement attributed to strategic cost management efforts and encouraging progress in the company’s product pipeline.
Moreover, the University of Texas Medical Branch in Galveston has been designated as a new Qualified Treatment Center for ZEVASKYN, Abeona’s U.S. Food and Drug Administration (FDA) approved gene therapy used to treat recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder. This expansion of treatment centers enhances patient access to this novel therapy.
The company also announced a key leadership appointment with Mohamad Tabrizi assuming the role of Senior Vice President and Chief Business Officer. In this capacity, Tabrizi will steer corporate strategy and business development initiatives, aiming to leverage Abeona’s foothold in rare genetic diseases.
On the analyst front, Cantor Fitzgerald has reaffirmed its Overweight rating on Abeona Therapeutics with a price target maintained at $28.00 per share, signaling optimism in the company's focus on innovative gene therapies. Conversely, Stifel has revised its price target downward from $20.00 to $19.00, reflecting concerns related to a delay in the commercial rollout of Zevaskyn. This delay stems from a temporary suspension in patient biopsy collection, which was necessitated by a performance issue linked to an FDA-mandated sterility assay.
These developments collectively underscore Abeona's ongoing commitment to advancing its gene therapy platforms amid operational challenges, while insiders remain actively managing equity positions related to reward compensations.